LCGC Asia Pacific
Atlantis T3 HPLC columns are a universal silica-based, reversed-phase C18 columns that retain and separate highly polar compounds. The T3 bonding uses a trifunctional C18 alkyl phase bonded at a ligand density that promotes polar compound retention and aqueous mobile phase compatibility.
The Waters proprietary* Optimum Bed Density (OBD) design combines high-pressure slurry packing with a carefully calculated axial compression element localized at the less-dense inlet end of the bed. This establishes predictable, uniform density profiles throughout the column and results in exceptional resistance to mechanical chromatographic bed failure. In addition, the OBD design delivers consistent column-to-column performance, reducing cost through extended lifetimes.
The current work highlights the use of Atlantis T3 columns for the analytical and preparative separation of polar β-blockers. The initial separation was developed on a 4.6 × 100 mm, 5 μm analytical column, and subsequently scaled to both 19 mm and 30 mm i.d. columns. The ability to inject high mass loads of polar compounds corresponds to less preparative runs and faster library screening and purification.
Figure 1
System: 2525 Binary Gradient Module, 2767 Sample Manager, 2996 PDA (AutoPurification flow cell)
Columns: Indicated on figure
Mobile phase: A: 0.1% TFA in water B: 0.1% TFA in ACN
Gradient: Initial hold at 0% B for 1 min, to 18% in 2.5 min, to 36% B in 5 min, hold at 100% B for 1 min, reset (13 min total cycle time)
Flow-rate: 25.59 mL/min
Injection: 1280 μL (44.8 mg total mass load)
Temperature: Ambient
Detection: UV @ 280 nm
Samples: Pyridoxine (5 mg/mL in H2O), acetaminophen (10 mg/mL in H2O), caffeine (20 mg/mL in H2O)
Figure 1
Figure 2
System: 2525 Binary Gradient Module, 2767 Sample Manager, 2996 PDA (AutoPurification flow cell)
Columns: Indicated on figure
Mobile phase: A: 0.1% formic acid in water B: 0.1% formic acid in ACN
Temperature: Ambient
Detection: UV @ 280 nm
Samples: Atenolol (40 mg/mL in DMSO), metropolol (200 mg/mL in DMSO), caffeine (200 mg/mL in DMSO)
Figure 2
Gradient conditions, flow-rate and injection volume are indicated on the chromatograms.
Polar compounds present a unique and difficult challenge in preparative chromatography, because these analytes are not usually retained and/or poorly separated by reversed-phase (RP) HPLC. Figure 1 shows the preparative separation of a mixture of polar analytes on both the Atlantis Prep T3 OBD column and a traditional C18 column. Note that the retention of all compounds is much greater on Atlantis T3. In addition, the most polar compound (pyridoxine) exhibits split peak shape on the traditional C18 prep column because of its inability to retain pyridoxine properly. This problem is eliminated with the T3 prep column.
To demonstrate the linearity of scale-up between analytical and preparative dimensions, a separation of polar β-blockers was developed on a 4.6 × 100 mm, 5 μm Atlantis T3 column [Figure 2(a)]. Flow-rate, injection volume and gradient conditions were then scaled linearly to 19 × 100 mm, 5 μm [Figure 2(b)] and 30 × 100 mm, 5 μm columns [Figure 2(c)]. No resolution is lost between the analytical and preparative separations because all columns are packed with the same particle size sorbent. This example not only demonstrates that the Atlantis T3 columns can be operated at 100% aqueous starting conditions, but also that analytical scouting runs can accurately predict the chromatographic behaviour of polar compounds on the preparative scale.
An analytical method for the separation of polar b-blockers was developed and linearly scaled to the preparative dimension. Because the Atlantis T3 column was designed specifically for retention and separation of these types of compounds, it is capable of operating at 100% aqueous conditions. Just like their analytical equivalents, Atlantis T3 preparative OBD columns retain compounds longer. Therefore, stronger mobile phases and/or steeper gradient profiles can now be used, which results in more volatile peak fractions, faster fraction evaporation, less sample handling and higher recoveries.
*UK Patent Number: GB2408469
© 2007 Waters Corporation. Waters, The Science of What's Possible, Atlantis, OBD and AutoPurification are trademarks of Waters Corporation.
Kenneth J. Fountain, Steven M. Collier and Diane M. Diehl, Waters Corp., Milford, Massachusetts, USA.
Waters Corporation
34 Maple Street, Milford, Massachusetts 01757, USA
tel. +1 508 478 2000 fax +1 508 478 1990
Website: www.waters.com
LC/MS Based Characterization Workflow of GLP-1 Therapeutic Peptide Liraglutide and Its Impurities
January 14th 2025This application note demonstrates a liquid chromatography/quadrupole time-of-flight mass spectrometer (LC/Q-TOF MS) workflow for the identification and characterization of therapeutic peptides.
Frontage Laboratories Streamlines their Product Lifecycle Management with NuGenesis™ LMS
January 9th 2025Frontage laboratories wanted to improve the efficiency and quality of their operations and invest in ways to streamline their workflows. They implemented Waters NuGenesis™ Lab Management System (LMS) to progress their digital transformation journey and combine synergistic data, workflow, and sample management capabilities to support the entire product lifecycle from discovery through manufacturing.